CS Diagnostics Corp. (OTC:CSDX) Engages Consultants for Key FDA Approval

Approval from the United States Food and Drug Administration can be a challenging process, and hence, healthcare companies like CS Diagnostics Corp. (OTC:CSDX) need specialized help in that matter. In a new development, the company announced yesterday that it had engaged the services of Lachman Consultants Inc. for FDA approval of one of its products.

The Key Details

In the news release, CS Diagnostics Corp announced that it was excited to have engaged the services of the above-mentioned consultants. The Westbury, New York-based Lachman Consultants would help CS Diagnostics Corp with regulatory expertise and skills to help with FDA approval for its CS-Protect Hydrogel product. The product in question functions as an organ spacer medical device and requires regulatory clearance.

Further Information

The company went on to note that in a departure from previous products, the CS-Protect Hydrogel was significantly more versatile and could be used in case of other pathological conditions as well. Lachman has been in business since 1978 and has provided such expertise to a range of clients pertaining to compliance and regulatory issues. It may be a good idea to add the CS Diagnostics Corp stock to your watch lists.

Thomas Fahrhoefer, President of the Board at CS Diagnostics Corp., added:

“The easy application of the CS-Protect Hydrogel being a ready-to-use product after removal from sterile packaging and unrequired further work steps eliminates any risk of contamination due to preparation and assembly of the product exclusion of another hygienic risk area within the treatment room. Also, no risk of wrong mixture, especially wrong sequence, and therefore no potential patient’s missed treatments. “